Compare Figs Inc (FIGS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Novo Nordisk A/S — how do they compare? Figs Inc trades at $15.24 (market cap $2.49B), while Novo Nordisk A/S trades at $38.41 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 66.4× Figs Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Novo Nordisk A/S for 116 Days on average.
| FIGS | NVO | |
|---|---|---|
Market Cap | $2.49B | $165.31B |
Volume | 5,964,311 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $63.98 |
52-Week Low | $6.90 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $2.25B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.
Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
